APO Research
Talk to an analyst

APO RESEARCH · REPORT

Trigger Point Injections Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Trigger Point Injections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchTrigger Point Injections Drugs Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Trigger Point Injections Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Trigger Point Injections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Trigger Point Injections Drugs Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Trigger Point Injections Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Trigger Point Injections Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Trigger Point Injections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Trigger Point Injections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Trigger Point Injections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Trigger Point Injections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Trigger Point Injections Drugs include Allergan, Anuh Pharma, Axplora, Boehringer Ingelheim, Bristol Myers Squibb, Cipla, EUROAPI, GlaxoSmithKline and Hospira, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Trigger Point Injections Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Trigger Point Injections Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Trigger Point Injections Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Trigger Point Injections Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Trigger Point Injections Drugs Segment by Company

Allergan

Anuh Pharma

Axplora

Boehringer Ingelheim

Bristol Myers Squibb

Cipla

EUROAPI

GlaxoSmithKline

Hospira

Hovione

Ipsen

Regeneron Pharmaceuticals

Steroid

Symbiotec Pharmalab

Teva Pharmaceuticals

Wellona Pharma

Zimmer Biomet

Bayer

GSK

Pfizer

Mylan

Sun Pharmaceutical

Trigger Point Injections Drugs Segment by Type

Botulinum Toxin (Botox)

Corticosteroids

Local Anesthetics

Platelet-Rich Plasma (PRP)

Other Agents

Trigger Point Injections Drugs Segment by Application

Surgical

Medical Diagnosis

Intensive Care Area (ICU)

Trigger Point Injections Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trigger Point Injections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Trigger Point Injections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trigger Point Injections Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Trigger Point Injections Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Trigger Point Injections Drugs industry.

Chapter 3: Detailed analysis of Trigger Point Injections Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Trigger Point Injections Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Trigger Point Injections Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Botulinum Toxin (Botox) Table 3. Key Players of Corticosteroids Table 4. Key Players of Local Anesthetics Table 3. Key Players of Platelet-Rich Plasma (PRP) Table 4. Key Players of Other Agents Table 5. Global Trigger Point Injections Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Surgical Table 7. Key Players of Medical Diagnosis Table 8. Key Players of Intensive Care Area (ICU) Table 9. Global Trigger Point Injections Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Trigger Point Injections Drugs Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Trigger Point Injections Drugs Market Share by Region (2021-2026) Table 12. Global Trigger Point Injections Drugs Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Trigger Point Injections Drugs Market Share by Region (2027-2032) Table 14. Trigger Point Injections Drugs Industry Trends Table 15. Trigger Point Injections Drugs Industry Drivers Table 16. Trigger Point Injections Drugs Industry Opportunities and Challenges Table 17. Trigger Point Injections Drugs Industry Restraints Table 18. Global Trigger Point Injections Drugs Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Trigger Point Injections Drugs Revenue Market Share by Company (2021-2026) Table 20. Global Trigger Point Injections Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Trigger Point Injections Drugs Key Company Head Office and Area Served Table 22. Global Trigger Point Injections Drugs Company, Product Type & Application Table 23. Global Trigger Point Injections Drugs Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Trigger Point Injections Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Trigger Point Injections Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Trigger Point Injections Drugs Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Trigger Point Injections Drugs Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Trigger Point Injections Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Trigger Point Injections Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Trigger Point Injections Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Trigger Point Injections Drugs Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Trigger Point Injections Drugs Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Trigger Point Injections Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Trigger Point Injections Drugs Revenue Market Share by Application (2027-2032) Table 36. Allergan Company Information Table 37. Allergan Business Overview Table 38. Allergan Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Allergan Trigger Point Injections Drugs Product Portfolio Table 40. Allergan Recent Development Table 41. Anuh Pharma Company Information Table 42. Anuh Pharma Business Overview Table 43. Anuh Pharma Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Anuh Pharma Trigger Point Injections Drugs Product Portfolio Table 45. Anuh Pharma Recent Development Table 46. Axplora Company Information Table 47. Axplora Business Overview Table 48. Axplora Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Axplora Trigger Point Injections Drugs Product Portfolio Table 50. Axplora Recent Development Table 51. Boehringer Ingelheim Company Information Table 52. Boehringer Ingelheim Business Overview Table 53. Boehringer Ingelheim Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Boehringer Ingelheim Trigger Point Injections Drugs Product Portfolio Table 55. Boehringer Ingelheim Recent Development Table 56. Bristol Myers Squibb Company Information Table 57. Bristol Myers Squibb Business Overview Table 58. Bristol Myers Squibb Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Bristol Myers Squibb Trigger Point Injections Drugs Product Portfolio Table 60. Bristol Myers Squibb Recent Development Table 61. Cipla Company Information Table 62. Cipla Business Overview Table 63. Cipla Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Cipla Trigger Point Injections Drugs Product Portfolio Table 65. Cipla Recent Development Table 66. EUROAPI Company Information Table 67. EUROAPI Business Overview Table 68. EUROAPI Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. EUROAPI Trigger Point Injections Drugs Product Portfolio Table 70. EUROAPI Recent Development Table 71. GlaxoSmithKline Company Information Table 72. GlaxoSmithKline Business Overview Table 73. GlaxoSmithKline Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. GlaxoSmithKline Trigger Point Injections Drugs Product Portfolio Table 75. GlaxoSmithKline Recent Development Table 76. Hospira Company Information Table 77. Hospira Business Overview Table 78. Hospira Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Hospira Trigger Point Injections Drugs Product Portfolio Table 80. Hospira Recent Development Table 81. Hovione Company Information Table 82. Hovione Business Overview Table 83. Hovione Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Hovione Trigger Point Injections Drugs Product Portfolio Table 85. Hovione Recent Development Table 86. Ipsen Company Information Table 87. Ipsen Business Overview Table 88. Ipsen Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Ipsen Trigger Point Injections Drugs Product Portfolio Table 90. Ipsen Recent Development Table 91. Regeneron Pharmaceuticals Company Information Table 92. Regeneron Pharmaceuticals Business Overview Table 93. Regeneron Pharmaceuticals Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Regeneron Pharmaceuticals Trigger Point Injections Drugs Product Portfolio Table 95. Regeneron Pharmaceuticals Recent Development Table 96. Steroid Company Information Table 97. Steroid Business Overview Table 98. Steroid Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Steroid Trigger Point Injections Drugs Product Portfolio Table 100. Steroid Recent Development Table 101. Symbiotec Pharmalab Company Information Table 102. Symbiotec Pharmalab Business Overview Table 103. Symbiotec Pharmalab Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Symbiotec Pharmalab Trigger Point Injections Drugs Product Portfolio Table 105. Symbiotec Pharmalab Recent Development Table 106. Teva Pharmaceuticals Company Information Table 107. Teva Pharmaceuticals Business Overview Table 108. Teva Pharmaceuticals Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. Teva Pharmaceuticals Trigger Point Injections Drugs Product Portfolio Table 110. Teva Pharmaceuticals Recent Development Table 111. Wellona Pharma Company Information Table 112. Wellona Pharma Business Overview Table 113. Wellona Pharma Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Wellona Pharma Trigger Point Injections Drugs Product Portfolio Table 115. Wellona Pharma Recent Development Table 116. Zimmer Biomet Company Information Table 117. Zimmer Biomet Business Overview Table 118. Zimmer Biomet Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. Zimmer Biomet Trigger Point Injections Drugs Product Portfolio Table 120. Zimmer Biomet Recent Development Table 121. Bayer Company Information Table 122. Bayer Business Overview Table 123. Bayer Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Bayer Trigger Point Injections Drugs Product Portfolio Table 125. Bayer Recent Development Table 126. GSK Company Information Table 127. GSK Business Overview Table 128. GSK Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. GSK Trigger Point Injections Drugs Product Portfolio Table 130. GSK Recent Development Table 131. Pfizer Company Information Table 132. Pfizer Business Overview Table 133. Pfizer Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 134. Pfizer Trigger Point Injections Drugs Product Portfolio Table 135. Pfizer Recent Development Table 136. Mylan Company Information Table 137. Mylan Business Overview Table 138. Mylan Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 139. Mylan Trigger Point Injections Drugs Product Portfolio Table 140. Mylan Recent Development Table 141. Sun Pharmaceutical Company Information Table 142. Sun Pharmaceutical Business Overview Table 143. Sun Pharmaceutical Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 144. Sun Pharmaceutical Trigger Point Injections Drugs Product Portfolio Table 145. Sun Pharmaceutical Recent Development Table 146. North America Trigger Point Injections Drugs Market Size by Type (2021-2026) & (US$ Million) Table 147. North America Trigger Point Injections Drugs Market Size by Type (2027-2032) & (US$ Million) Table 148. North America Trigger Point Injections Drugs Market Size by Application (2021-2026) & (US$ Million) Table 149. North America Trigger Point Injections Drugs Market Size by Application (2027-2032) & (US$ Million) Table 150. North America Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. North America Trigger Point Injections Drugs Market Size by Country (2021-2026) Table 152. North America Trigger Point Injections Drugs Market Size by Country (2027-2032) Table 153. Europe Trigger Point Injections Drugs Market Size by Type (2021-2026) & (US$ Million) Table 154. Europe Trigger Point Injections Drugs Market Size by Type (2027-2032) & (US$ Million) Table 155. Europe Trigger Point Injections Drugs Market Size by Application (2021-2026) & (US$ Million) Table 156. Europe Trigger Point Injections Drugs Market Size by Application (2027-2032) & (US$ Million) Table 157. Europe Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe Trigger Point Injections Drugs Market Size by Country (2021-2026) Table 159. Europe Trigger Point Injections Drugs Market Size by Country (2027-2032) Table 160. China Trigger Point Injections Drugs Market Size by Type (2021-2026) & (US$ Million) Table 161. China Trigger Point Injections Drugs Market Size by Type (2027-2032) & (US$ Million) Table 162. China Trigger Point Injections Drugs Market Size by Application (2021-2026) & (US$ Million) Table 163. China Trigger Point Injections Drugs Market Size by Application (2027-2032) & (US$ Million) Table 164. Asia Trigger Point Injections Drugs Market Size by Type (2021-2026) & (US$ Million) Table 165. Asia Trigger Point Injections Drugs Market Size by Type (2027-2032) & (US$ Million) Table 166. Asia Trigger Point Injections Drugs Market Size by Application (2021-2026) & (US$ Million) Table 167. Asia Trigger Point Injections Drugs Market Size by Application (2027-2032) & (US$ Million) Table 168. Asia Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia Trigger Point Injections Drugs Market Size by Country (2021-2026) Table 170. Asia Trigger Point Injections Drugs Market Size by Country (2027-2032) Table 171. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Type (2021-2026) & (US$ Million) Table 172. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Type (2027-2032) & (US$ Million) Table 173. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Application (2021-2026) & (US$ Million) Table 174. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Application (2027-2032) & (US$ Million) Table 175. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2021-2026) Table 177. South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources Table 181. Primary Sources List of Figures Figure 1. Trigger Point Injections Drugs Product Image Figure 2. Global Trigger Point Injections Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Trigger Point Injections Drugs Market Share by Type: 2025 VS 2032 Figure 4. Botulinum Toxin (Botox) Image Figure 5. Corticosteroids Image Figure 6. Local Anesthetics Image Figure 7. Platelet-Rich Plasma (PRP) Image Figure 8. Other Agents Image Figure 9. Global Trigger Point Injections Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Trigger Point Injections Drugs Market Share by Application: 2025 VS 2032 Figure 11. Surgical Image Figure 12. Medical Diagnosis Image Figure 13. Intensive Care Area (ICU) Image Figure 14. Global Trigger Point Injections Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 16. Global Trigger Point Injections Drugs Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Trigger Point Injections Drugs Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Trigger Point Injections Drugs Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Trigger Point Injections Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Trigger Point Injections Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global Trigger Point Injections Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Trigger Point Injections Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 26. North America Trigger Point Injections Drugs Market Share by Type (2021-2032) Figure 27. North America Trigger Point Injections Drugs Market Share by Application (2021-2032) Figure 28. North America Trigger Point Injections Drugs Market Share by Country (2021-2032) Figure 29. United States Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Canada Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 32. Europe Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 33. Europe Trigger Point Injections Drugs Market Share by Type (2021-2032) Figure 34. Europe Trigger Point Injections Drugs Market Share by Application (2021-2032) Figure 35. Europe Trigger Point Injections Drugs Market Share by Country (2021-2032) Figure 36. Germany Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 37. France Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Italy Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 40. Russia Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 42. China Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 43. China Trigger Point Injections Drugs Market Share by Type (2021-2032) Figure 44. China Trigger Point Injections Drugs Market Share by Application (2021-2032) Figure 45. Asia Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 46. Asia Trigger Point Injections Drugs Market Share by Type (2021-2032) Figure 47. Asia Trigger Point Injections Drugs Market Share by Application (2021-2032) Figure 48. Asia Trigger Point Injections Drugs Market Share by Country (2021-2032) Figure 49. Japan Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 53. India Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 54. Australia Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Trigger Point Injections Drugs Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Trigger Point Injections Drugs Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Trigger Point Injections Drugs Market Share by Country (2021-2032) Figure 59. Brazil Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 64. UAE Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Chile Trigger Point Injections Drugs Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Botulinum Toxin (Botox)
  • Corticosteroids
  • Local Anesthetics
  • Platelet-Rich Plasma (PRP)
  • Other Agents
Applications
  • Surgical
  • Medical Diagnosis
  • Intensive Care Area (ICU)
Companies covered
  • Allergan
  • Anuh Pharma
  • Axplora
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cipla
  • EUROAPI
  • GlaxoSmithKline
  • Hospira
  • Hovione
  • Ipsen
  • Regeneron Pharmaceuticals
  • Steroid
  • Symbiotec Pharmalab
  • Teva Pharmaceuticals
  • Wellona Pharma
  • Zimmer Biomet
  • Bayer
  • GSK
  • Pfizer
  • Mylan
  • Sun Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Trigger Point Injections Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Botulinum Toxin (Botox)
  5. 1.2.3 Corticosteroids
  6. 1.2.4 Local Anesthetics
  7. 1.2.5 Platelet-Rich Plasma (PRP)
  8. 1.2.6 Other Agents
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Trigger Point Injections Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Surgical
  12. 1.3.3 Medical Diagnosis
  13. 1.3.4 Intensive Care Area (ICU)
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Trigger Point Injections Drugs Growth Trends by Region
  16. 1.5.1 Global Trigger Point Injections Drugs Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Trigger Point Injections Drugs Market Size by Region (2021-2026)
  18. 1.5.3 Trigger Point Injections Drugs Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Trigger Point Injections Drugs Market Dynamics
  1. 2.1 Trigger Point Injections Drugs Industry Trends
  2. 2.2 Trigger Point Injections Drugs Industry Drivers
  3. 2.3 Trigger Point Injections Drugs Industry Opportunities and Challenges
  4. 2.4 Trigger Point Injections Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Trigger Point Injections Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Trigger Point Injections Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Trigger Point Injections Drugs Key Company Head office and Area Served
  4. 3.4 Global Trigger Point Injections Drugs Company, Product Type & Application
  5. 3.5 Global Trigger Point Injections Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Trigger Point Injections Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Trigger Point Injections Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Trigger Point Injections Drugs Tier 1, Tier 2, and Tier 3
4 Trigger Point Injections Drugs Market by Type
  1. 4.1 Global Trigger Point Injections Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Trigger Point Injections Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Trigger Point Injections Drugs Market Size Share by Type (2021-2032)
5 Trigger Point Injections Drugs Market by Application
  1. 5.1 Global Trigger Point Injections Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Trigger Point Injections Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Trigger Point Injections Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Allergan
  2. 6.1.1 Allergan Company Information
  3. 6.1.2 Allergan Business Overview
  4. 6.1.3 Allergan Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Allergan Trigger Point Injections Drugs Product Portfolio
  6. 6.1.5 Allergan Recent Developments
  7. 6.2 Anuh Pharma
  8. 6.2.1 Anuh Pharma Company Information
  9. 6.2.2 Anuh Pharma Business Overview
  10. 6.2.3 Anuh Pharma Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Anuh Pharma Trigger Point Injections Drugs Product Portfolio
  12. 6.2.5 Anuh Pharma Recent Developments
  13. 6.3 Axplora
  14. 6.3.1 Axplora Company Information
  15. 6.3.2 Axplora Business Overview
  16. 6.3.3 Axplora Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Axplora Trigger Point Injections Drugs Product Portfolio
  18. 6.3.5 Axplora Recent Developments
  19. 6.4 Boehringer Ingelheim
  20. 6.4.1 Boehringer Ingelheim Company Information
  21. 6.4.2 Boehringer Ingelheim Business Overview
  22. 6.4.3 Boehringer Ingelheim Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Boehringer Ingelheim Trigger Point Injections Drugs Product Portfolio
  24. 6.4.5 Boehringer Ingelheim Recent Developments
  25. 6.5 Bristol Myers Squibb
  26. 6.5.1 Bristol Myers Squibb Company Information
  27. 6.5.2 Bristol Myers Squibb Business Overview
  28. 6.5.3 Bristol Myers Squibb Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Bristol Myers Squibb Trigger Point Injections Drugs Product Portfolio
  30. 6.5.5 Bristol Myers Squibb Recent Developments
  31. 6.6 Cipla
  32. 6.6.1 Cipla Company Information
  33. 6.6.2 Cipla Business Overview
  34. 6.6.3 Cipla Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Cipla Trigger Point Injections Drugs Product Portfolio
  36. 6.6.5 Cipla Recent Developments
  37. 6.7 EUROAPI
  38. 6.7.1 EUROAPI Company Information
  39. 6.7.2 EUROAPI Business Overview
  40. 6.7.3 EUROAPI Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 EUROAPI Trigger Point Injections Drugs Product Portfolio
  42. 6.7.5 EUROAPI Recent Developments
  43. 6.8 GlaxoSmithKline
  44. 6.8.1 GlaxoSmithKline Company Information
  45. 6.8.2 GlaxoSmithKline Business Overview
  46. 6.8.3 GlaxoSmithKline Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 GlaxoSmithKline Trigger Point Injections Drugs Product Portfolio
  48. 6.8.5 GlaxoSmithKline Recent Developments
  49. 6.9 Hospira
  50. 6.9.1 Hospira Company Information
  51. 6.9.2 Hospira Business Overview
  52. 6.9.3 Hospira Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Hospira Trigger Point Injections Drugs Product Portfolio
  54. 6.9.5 Hospira Recent Developments
  55. 6.10 Hovione
  56. 6.10.1 Hovione Company Information
  57. 6.10.2 Hovione Business Overview
  58. 6.10.3 Hovione Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Hovione Trigger Point Injections Drugs Product Portfolio
  60. 6.10.5 Hovione Recent Developments
  61. 6.11 Ipsen
  62. 6.11.1 Ipsen Company Information
  63. 6.11.2 Ipsen Business Overview
  64. 6.11.3 Ipsen Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Ipsen Trigger Point Injections Drugs Product Portfolio
  66. 6.11.5 Ipsen Recent Developments
  67. 6.12 Regeneron Pharmaceuticals
  68. 6.12.1 Regeneron Pharmaceuticals Company Information
  69. 6.12.2 Regeneron Pharmaceuticals Business Overview
  70. 6.12.3 Regeneron Pharmaceuticals Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Regeneron Pharmaceuticals Trigger Point Injections Drugs Product Portfolio
  72. 6.12.5 Regeneron Pharmaceuticals Recent Developments
  73. 6.13 Steroid
  74. 6.13.1 Steroid Company Information
  75. 6.13.2 Steroid Business Overview
  76. 6.13.3 Steroid Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Steroid Trigger Point Injections Drugs Product Portfolio
  78. 6.13.5 Steroid Recent Developments
  79. 6.14 Symbiotec Pharmalab
  80. 6.14.1 Symbiotec Pharmalab Company Information
  81. 6.14.2 Symbiotec Pharmalab Business Overview
  82. 6.14.3 Symbiotec Pharmalab Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Symbiotec Pharmalab Trigger Point Injections Drugs Product Portfolio
  84. 6.14.5 Symbiotec Pharmalab Recent Developments
  85. 6.15 Teva Pharmaceuticals
  86. 6.15.1 Teva Pharmaceuticals Company Information
  87. 6.15.2 Teva Pharmaceuticals Business Overview
  88. 6.15.3 Teva Pharmaceuticals Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Teva Pharmaceuticals Trigger Point Injections Drugs Product Portfolio
  90. 6.15.5 Teva Pharmaceuticals Recent Developments
  91. 6.16 Wellona Pharma
  92. 6.16.1 Wellona Pharma Company Information
  93. 6.16.2 Wellona Pharma Business Overview
  94. 6.16.3 Wellona Pharma Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Wellona Pharma Trigger Point Injections Drugs Product Portfolio
  96. 6.16.5 Wellona Pharma Recent Developments
  97. 6.17 Zimmer Biomet
  98. 6.17.1 Zimmer Biomet Company Information
  99. 6.17.2 Zimmer Biomet Business Overview
  100. 6.17.3 Zimmer Biomet Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Zimmer Biomet Trigger Point Injections Drugs Product Portfolio
  102. 6.17.5 Zimmer Biomet Recent Developments
  103. 6.18 Bayer
  104. 6.18.1 Bayer Company Information
  105. 6.18.2 Bayer Business Overview
  106. 6.18.3 Bayer Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Bayer Trigger Point Injections Drugs Product Portfolio
  108. 6.18.5 Bayer Recent Developments
  109. 6.19 GSK
  110. 6.19.1 GSK Company Information
  111. 6.19.2 GSK Business Overview
  112. 6.19.3 GSK Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 GSK Trigger Point Injections Drugs Product Portfolio
  114. 6.19.5 GSK Recent Developments
  115. 6.20 Pfizer
  116. 6.20.1 Pfizer Company Information
  117. 6.20.2 Pfizer Business Overview
  118. 6.20.3 Pfizer Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Pfizer Trigger Point Injections Drugs Product Portfolio
  120. 6.20.5 Pfizer Recent Developments
  121. 6.21 Mylan
  122. 6.21.1 Mylan Company Information
  123. 6.21.2 Mylan Business Overview
  124. 6.21.3 Mylan Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Mylan Trigger Point Injections Drugs Product Portfolio
  126. 6.21.5 Mylan Recent Developments
  127. 6.22 Sun Pharmaceutical
  128. 6.22.1 Sun Pharmaceutical Company Information
  129. 6.22.2 Sun Pharmaceutical Business Overview
  130. 6.22.3 Sun Pharmaceutical Trigger Point Injections Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 Sun Pharmaceutical Trigger Point Injections Drugs Product Portfolio
  132. 6.22.5 Sun Pharmaceutical Recent Developments
7 North America
  1. 7.1 North America Trigger Point Injections Drugs Market Size (2021-2032)
  2. 7.2 North America Trigger Point Injections Drugs Market Size by Type
  3. 7.2.1 North America Trigger Point Injections Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Trigger Point Injections Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Trigger Point Injections Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Trigger Point Injections Drugs Market Size by Application
  7. 7.3.1 North America Trigger Point Injections Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Trigger Point Injections Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Trigger Point Injections Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Trigger Point Injections Drugs Market Size by Country
  11. 7.4.1 North America Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Trigger Point Injections Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Trigger Point Injections Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Trigger Point Injections Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Trigger Point Injections Drugs Market Size (2021-2032)
  2. 8.2 Europe Trigger Point Injections Drugs Market Size by Type
  3. 8.2.1 Europe Trigger Point Injections Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Trigger Point Injections Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Trigger Point Injections Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Trigger Point Injections Drugs Market Size by Application
  7. 8.3.1 Europe Trigger Point Injections Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Trigger Point Injections Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Trigger Point Injections Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Trigger Point Injections Drugs Market Size by Country
  11. 8.4.1 Europe Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Trigger Point Injections Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Trigger Point Injections Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Trigger Point Injections Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Trigger Point Injections Drugs Market Size (2021-2032)
  2. 9.2 China Trigger Point Injections Drugs Market Size by Type
  3. 9.2.1 China Trigger Point Injections Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Trigger Point Injections Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Trigger Point Injections Drugs Market Share by Type (2021-2032)
  6. 9.3 China Trigger Point Injections Drugs Market Size by Application
  7. 9.3.1 China Trigger Point Injections Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Trigger Point Injections Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Trigger Point Injections Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Trigger Point Injections Drugs Market Size (2021-2032)
  2. 10.2 Asia Trigger Point Injections Drugs Market Size by Type
  3. 10.2.1 Asia Trigger Point Injections Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Trigger Point Injections Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Trigger Point Injections Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Trigger Point Injections Drugs Market Size by Application
  7. 10.3.1 Asia Trigger Point Injections Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Trigger Point Injections Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Trigger Point Injections Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Trigger Point Injections Drugs Market Size by Country
  11. 10.4.1 Asia Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Trigger Point Injections Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Trigger Point Injections Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Trigger Point Injections Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Trigger Point Injections Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Trigger Point Injections Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Trigger Point Injections Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Trigger Point Injections Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst